FLT3-ITD+ AML: recent trial updates, novel approaches, and MRD

This podcast focuses on FLT3-ITD-positive acute myeloid leukemia (FLT3-ITD+ AML), featuring experts Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Harry Erba, MD, PhD, Duke University, Durham, NC. The episode covers the standard of care for frontline treatment, key trial updates including an analysis of the Quantum-First trial (NCT02668653), and the use of measurable residual disease (MRD) using FLT3-ITD as a marker.